Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database

This study aimed to compare persistence and adherence with the beta‐3‐adrenoceptor agonist mirabegron (MIR) vs AMs over 12 months. Patients and MethodsThis retrospective cohort analysis included patients aged ≥18 years who were prescribed MIR, or any AM. A 12‐month look‐back was used to assess inclusion eligibility. The primary end‐point was persistence, defined as time to first discontinuation of index drug, during 1 year follow‐up. The secondary end‐point was adherence, estimated by medication possession ratio (MPR). ResultsInclusion criteria were met by 6189 patients. Those prescribed AMs were mostly treatment‐naïve (range 72.9%‐95.3%) vs 54.4% of MIR patients. There was greater persistence with MIR vs AM. The median number of days on therapy with MIR was 101, vs 27‐56 for AMs. Patients receiving AMs were significantly more likely to discontinue than those receiving MIR (hazard ratio [HR] range 1.24‐2.05, P < .01 for each AM vs MIR. In treatment‐naïve patients, HRs ranged from 1.25 (solifenacin, P = .012) to 2.07 (oxybutynin IR, P < .001). In treatment‐experienced patients, they ranged from 1.10 (fesoterodine, P = NS) to 2.12 (oxybutynin IR, P < .001). Adherence was greater with MIR (mean MPR 48.4%) than with AMs (range 27.6%‐40.4%, P < .001). Treatment‐experienced patients were significantly less likely to discontinue treatment (HR 0.87, P = .006). Discussion and conclusionMIR was associated with a significant...
Source: International Journal of Clinical Practice - Category: Internal Medicine Authors: Tags: ORIGINAL PAPER Source Type: research